A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ

Cannabinoid receptors (CB) are expressed throughout human skin epithelium. CB1 activation inhibits human hair growth and decreases proliferation of epidermal keratinocytes. Since psoriasis is a chronic hyperproliferative, inflammatory skin disease, it is conceivable that the therapeutic modulation of CB signaling, which can inhibit both proliferation and inflammation, could win a place in future psoriasis management. Given that psoriasis is characterized by up-regulation of keratins K6 and K16, we have investigated whether CB1 stimulation modulates their expression in human epidermis. Treatment of organ-cultured human skin with the CB1-specific agonist, arachidonoyl-chloro-ethanolamide (ACEA), decreased K6 and K16 staining intensity in situ. At the gene and protein levels, ACEA also decreased K6 expression of cultured HaCaT keratinocytes, which show some similarities to psoriatic keratinocytes. These effects were partly antagonized by the CB1-specific antagonist, AM251. While CB1-mediated signaling also significantly inhibited human epidermal keratinocyte proliferation in situ, as shown by K6/Ki-67-double immunofluorescence, the inhibitory effect of ACEA on K6 expression in situ was independent of its anti-proliferative effect. Given recent appreciation of the role of K6 as a functionally important protein that regulates epithelial wound healing in mice, it is conceivable that the novel CB1-mediated regulation of keratin 6/16 revealed here also is relevant to wound healing. Taken together, our results suggest that cannabinoids and their receptors constitute a novel, clinically relevant control element of human K6 and K16 expression.

[1]  R. V. Van Dross,et al.  Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth. , 2013, Life sciences.

[2]  N. Balato,et al.  IL‐33 is secreted by psoriatic keratinocytes and induces pro‐inflammatory cytokines via keratinocyte and mast cell activation , 2012, Experimental dermatology.

[3]  J. Bouwstra,et al.  Nature versus nurture: does human skin maintain its stratum corneum lipid properties in vitro? , 2012, Experimental dermatology.

[4]  P. Elias,et al.  Cannabinoid receptors 1 and 2 oppositely regulate epidermal permeability barrier status and differentiation , 2012, Experimental dermatology.

[5]  G. Nilsson,et al.  Experimentally induced psoriatic lesion associates with interleukin (IL)‐6 in mast cells and appearance of dermal cells expressing IL‐33 and IL‐6 receptor , 2012, Clinical and experimental immunology.

[6]  T. Bíró,et al.  Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells. , 2012, The Journal of investigative dermatology.

[7]  M. Bedoni,et al.  Etanercept restores a differentiated keratinocyte phenotype in psoriatic human skin: a morphological study , 2012, Experimental dermatology.

[8]  D. Simone,et al.  Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy , 2012, The Journal of Neuroscience.

[9]  P. Coulombe,et al.  A wound-induced keratin inhibits Src activity during keratinocyte migration and tissue repair , 2012, The Journal of cell biology.

[10]  A. Finazzi Agro',et al.  Endocannabinoids Stimulate Human Melanogenesis via Type-1 Cannabinoid Receptor* , 2012, The Journal of Biological Chemistry.

[11]  R. Paus,et al.  Endocannabinoids limit excessive mast cell maturation and activation in human skin. , 2012, The Journal of allergy and clinical immunology.

[12]  A. Bozek,et al.  The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions , 2012, Experimental dermatology.

[13]  T. Tencomnao,et al.  Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. , 2012, Genetics and molecular research : GMR.

[14]  P. Currie,et al.  The cannabinoid receptor CB1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala , 2012, Neuropharmacology.

[15]  R. Paus,et al.  Thyrotropin-releasing hormone controls mitochondrial biology in human epidermis. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  L. Marnett,et al.  Cannabinoids, endocannabinoids, and cancer , 2011, Cancer and Metastasis Reviews.

[17]  D. Byamba,et al.  Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment , 2011, Experimental dermatology.

[18]  M. Bernier,et al.  The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen‐related receptor α protein , 2011, British journal of pharmacology.

[19]  H. Kurzen,et al.  The cholinergic system in guttate psoriasis with special reference to mast cells , 2011, Experimental dermatology.

[20]  D. Sasseville,et al.  CD109 release from the cell surface in human keratinocytes regulates TGF‐β receptor expression, TGF‐β signalling and STAT3 activation: relevance to psoriasis , 2011, Experimental dermatology.

[21]  Y. Ramot,et al.  Spermidine Promotes Human Hair Growth and Is a Novel Modulator of Human Epithelial Stem Cell Functions , 2011, PloS one.

[22]  S. Koo,et al.  Cannabinoid Receptor Type 1 (CB1R) Signaling Regulates Hepatic Gluconeogenesis via Induction of Endoplasmic Reticulum-bound Transcription Factor cAMP-responsive Element-binding Protein H (CREBH) in Primary Hepatocytes* , 2011, The Journal of Biological Chemistry.

[23]  R. Paus,et al.  Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. , 2011, The Journal of investigative dermatology.

[24]  Yiwei Zhao,et al.  Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. , 2011, The Journal of investigative dermatology.

[25]  D. Leake,et al.  Development of quantitative molecular clinical end points for siRNA clinical trials. , 2011, The Journal of investigative dermatology.

[26]  T. Tencomnao,et al.  Effects of Thai Medicinal Herb Extracts with Anti-Psoriatic Activity on the Expression on NF-κB Signaling Biomarkers in HaCaT Keratinocytes , 2011, Molecules.

[27]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[28]  Rosaleen J. Anderson,et al.  Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay. , 2010, Assay and drug development technologies.

[29]  K. Altmann,et al.  Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. , 2010, Biochemical pharmacology.

[30]  Y. Ramot,et al.  Prolactin—a novel neuroendocrine regulator of human keratin expression in situ , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  R. Paus,et al.  Thyrotropin powers human mitochondria , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Y. Ramot,et al.  Thyrotropin‐releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro , 2010, The British journal of dermatology.

[33]  I. Maruyama,et al.  Involvement of the endocannabinoid system in periodontal healing. , 2010, Biochemical and biophysical research communications.

[34]  Y. Ramot,et al.  Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. , 2010, Endocrinology.

[35]  G. Nilsson,et al.  Increased mast cell expression of PAR‐2 in skin inflammatory diseases and release of IL‐8 upon PAR‐2 activation , 2010, Experimental dermatology.

[36]  E. Gáspár,et al.  The ‘melanocyte‐keratin’ mystery revisited: neither normal human epidermal nor hair follicle melanocytes express keratin 16 or keratin 6 in situ , 2009, The British journal of dermatology.

[37]  R. Paus,et al.  The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. , 2009, Trends in pharmacological sciences.

[38]  J. Szepietowski,et al.  Cannabinoid system in the skin – a possible target for future therapies in dermatology , 2009, Experimental dermatology.

[39]  J. Zwerina,et al.  The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. , 2009, Arthritis and rheumatism.

[40]  R. Paus,et al.  Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. , 2009, The Journal of investigative dermatology.

[41]  R. Paus,et al.  Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor‐2‐mediated signaling , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  R. Moll,et al.  The human keratins: biology and pathology , 2008, Histochemistry and Cell Biology.

[43]  M. Maccarrone,et al.  Anandamide Regulates Keratinocyte Differentiation by Inducing DNA Methylation in a CB1 Receptor-dependent Manner* , 2008, Journal of Biological Chemistry.

[44]  R. Paus,et al.  Inhibition of human hair follicle growth by endo‐and exocannabinoids , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  C. Griffiths,et al.  Pathogenesis and clinical features of psoriasis , 2007, The Lancet.

[46]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[47]  E. Williamson,et al.  Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. , 2007, Journal of dermatological science.

[48]  R. Paus,et al.  Towards the development of a simplified long‐term organ culture method for human scalp skin and its appendages under serum‐free conditions , 2007, Experimental dermatology.

[49]  P. V. D. van de Kerkhof,et al.  Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis , 2006, The British journal of dermatology.

[50]  T. Luger,et al.  [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. , 2006, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[51]  S. Ward,et al.  Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. , 2005, Gastroenterology.

[52]  T. Luger,et al.  Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. , 2005, Journal of dermatological science.

[53]  M. Namazi.  Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[54]  T. Klein.  Cannabinoid-based drugs as anti-inflammatory therapeutics , 2005, Nature Reviews Immunology.

[55]  A. Ishida-Yamamoto,et al.  Unique Keratinization Process in Psoriasis: Late Differentiation Markers Are Abolished Because of the Premature Cell Death , 2004, The Journal of dermatology.

[56]  A. Finazzi-Agro’,et al.  The Endocannabinoid System in Human Keratinocytes , 2003, Journal of Biological Chemistry.

[57]  P. V. D. van de Kerkhof,et al.  Changes in Keratin 6 and Keratin 10 (Co-)Expression in Lesional and Symptomless Skin of Spreading Psoriasis , 2000, Dermatology.

[58]  J. D. Richardson,et al.  Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors , 1998, Pain.

[59]  P. Coulombe,et al.  Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16 , 1996, The Journal of cell biology.

[60]  J. Jorcano,et al.  Elements Controlling the Expression and Induction of the Skin Hyperproliferation-associated Keratin K6 (*) , 1995, The Journal of Biological Chemistry.

[61]  R J Falk,et al.  Vitronectin: effects on keratinocyte motility and inhibition of collagen-induced motility. , 1991, The Journal of investigative dermatology.

[62]  N. Fusenig,et al.  Density-dependent modulation of synthesis of keratins 1 and 10 in the human keratinocyte line HACAT and in ras-transfected tumorigenic clones. , 1989, Differentiation; research in biological diversity.

[63]  J. Hornung,et al.  Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line , 1988, The Journal of cell biology.

[64]  K. Stenn,et al.  Epibolin: a protein of human plasma that supports epithelial cell movement. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Maag,et al.  Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. , 2012, Neurotoxicology.

[66]  A. Hohmann,et al.  Cannabinoid mechanisms of pain suppression. , 2005, Handbook of experimental pharmacology.

[67]  J. Schweizer,et al.  Keratins of the human hair follicle. , 2005, International review of cytology.

[68]  S. Jabłońska,et al.  Mast cells in the initial stages of psoriasis , 2004, Archives of Dermatological Research.

[69]  Antonello,et al.  The Endocannabinoid System in Human Keratinocytes. Evidence that Anandamide Inhibits Epidermal Differentiation through CB1 Receptor-Dependent Inhibition of Protein Kinase C, Activating Protein-1 and Transglutaminase* , 2003 .

[70]  Cristina Blázquez,et al.  Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. , 2003, The Journal of clinical investigation.

[71]  L. Kemény,et al.  Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT , 2001, Inflammation Research.